SEEL: יתרות המזומנים של החברה Seelos Therapeutics, Inc

A narrow specialization in intranasal drugs creates a strong dependence of Seelos Therapeutics (SEEL) on external financing. The company's cash dynamics reflect a current trend where 0.00 serves as the final level marker. Revenues rely on future insurance fund payments for depression treatment, although geopolitical tensions and sanctions may hinder international trials and raw material supplies.
פילוחי מדדים מקיפים ואנליטיקה עבור Seelos Therapeutics, Inc. (SEEL)

This indicator captures the real-time volume of liquid assets, excluding temporary gaps in quarterly reporting. For Seelos Therapeutics (SEEL), this is a critical resource that ensures the funding of costly intranasal ketamine trials under strict FDA oversight. The current cash balance stands at 0.00, which determines the startup's autonomy horizon. The trend of this metric allows for an assessment of the risk of capital depletion before the completion of clinical phases. A stable balance confirms the business's solvency and resilience.